Barclays analyst Geoff Meacham maintained a Hold rating on Biohaven Pharmaceutical Holding Co Ltd (BHVN) yesterday and set a price target of $55. The company’s shares opened today at $56.02.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 4.2% and a 53.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Kiniksa Pharmaceuticals Ltd, and Achillion Pharmaceuticals.
Biohaven Pharmaceutical Holding Co Ltd has an analyst consensus of Strong Buy, with a price target consensus of $76.63.
See today’s analyst top recommended stocks >>
The company has a one-year high of $65.64 and a one-year low of $29.17. Currently, Biohaven Pharmaceutical Holding Co Ltd has an average volume of 617.8K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.
